Streamlining Clinical Decision Support Through Integrated Education
Introduction
Clear Value Plus (CVP) is a clinical decision support (CDS) tool that guides providers toward evidence-based treatment options and highlights therapies aligned with Value Pathways powered by the National Comprehensive Cancer Network (NCCN). During CDS use, providers may need to consult external resources, such as clinical guidelines or disease-specific staging systems, which can disrupt workflow and delay care.
To address this, the Launch N’ Learn feature was developed and integrated into CVP. This enhancement introduces embedded, point-of-care links that provide direct access to relevant criteria required for clinical decision making. For example, staging criteria information is displayed when a user is prompted to enter a disease stage without leaving the CDS environment. This integration is designed to improve efficiency and support informed decision-making at the point of care.
Materials and Methods
In March 2025, in collaboration with the Value Pathways Task Force, Launch N’ Learn was implemented across 14 clinical assessments spanning 12 cancer diagnoses, aligned with the most current NCCN Guidelines. An educational campaign—including announcements and demo videos—supported the rollout.
Examples of embedded guidance include the Rai Staging System for chronic lymphocytic leukemia; the International Prognostic Index (IPI) and stage-modified IPI (smIPI) for diffuse large B-cell lymphoma; and the American Urological Association (AUA) Risk Stratification Tool for bladder cancer. System analytics were used to track utilization and inform future development.
Results
Between March and July 2025, Launch N’ Learn was accessed 457 times. The most frequently viewed resources were the smIPI and IPI for diffuse large B-cell lymphoma and the staging guidance for Hodgkin lymphoma. Additional usage was observed across multiple other cancer types (Table 1).
Conclusion
Launch N’ Learn enhances clinical decision-making by embedding guideline-based educational content directly within the CDS tool. Early usage data suggests strong provider engagement, especially with complex staging tools for hematologic malignancies.
Although promising, this evaluation is limited by its short follow-up period and the reliance on access counts as a proxy for clinical impact. Future directions include expanding disease coverage, refining content based on user feedback, and evaluating associations with Value Pathway adherence and clinical outcomes.
